The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Zynex, through its subsidiary, markets electro therapy products, which help improve the quality of life of patients who have functional disabilities.
On March 6, 2023, Zynex announced that the Company was postponing release of its fourth quarter and full year financial results and conference call initially scheduled for March 6, 2023 to allow additional time to complete its year-end closing procedures. On this news, the price of Zynex shares declined by $2.65 per share, or approximately 21.35%, from $12.41 per share to close at $9.76 on March 7, 2023.